Septerna, Inc. (NASDAQ:SEPN) CFO Buys $29,250.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie bought 5,000 shares of the stock in a transaction on Friday, February 21st. The shares were bought at an average price of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the transaction, the chief financial officer now directly owns 30,000 shares of the company’s stock, valued at $175,500. This trade represents a 20.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Septerna Price Performance

Shares of NASDAQ SEPN traded down $0.09 on Friday, hitting $5.80. The company’s stock had a trading volume of 1,158,707 shares, compared to its average volume of 586,476. Septerna, Inc. has a 12-month low of $4.17 and a 12-month high of $28.99. The company has a 50 day simple moving average of $17.78.

Institutional Trading of Septerna

Several institutional investors and hedge funds have recently modified their holdings of SEPN. Tower Research Capital LLC TRC purchased a new stake in shares of Septerna in the fourth quarter valued at about $25,000. New York State Common Retirement Fund purchased a new stake in shares of Septerna in the fourth quarter valued at about $32,000. Legal & General Group Plc purchased a new stake in shares of Septerna in the fourth quarter valued at about $42,000. Summit Investment Advisors Inc. purchased a new stake in shares of Septerna in the fourth quarter valued at about $45,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Septerna in the fourth quarter valued at about $52,000.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SEPN. TD Cowen began coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 target price on shares of Septerna in a research report on Tuesday, February 11th. Wells Fargo & Company lowered shares of Septerna from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $43.00 to $14.00 in a research report on Tuesday. Finally, JPMorgan Chase & Co. began coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.